IDrugs 2004-01-01

BNP-7787 (BioNumerik/Baxter Oncology/Grelan).

R Todd Reilly

Index: IDrugs 7(1) , 64-9, (2004)

Full Text: HTML

Abstract

BioNumerik Pharmacology Inc, Baxter Oncology GmbH (formerly ASTA Medica AG) and Grelan Pharmaceutical Co Ltd are developing BNP-7787 for the potential reduction of toxicity associated with cisplatin and carboplatin treatment in cancer patients.

Structure	Name/CAS No.	Molecular Formula	Articles
	Coenzyme M CAS:45127-11-5	C₄H₁₀O₆S₄

Mechanistic study of BNP7787-mediated cisplatin nephroprotec...
2011-02-01
[Cancer Chemother. Pharmacol. 67(2) , 381-91, (2011)]

Phase II randomized study of dose-dense docetaxel and cispla...
2008-10-01
[J. Thorac. Oncol. 3(10) , 1159-65, (2008)]

New approaches to drug discovery and development: a mechanis...
2003-07-01
[Cancer Chemother. Pharmacol. 52 Suppl 1 , S3-15, (2003)]

Mechanistic study of BNP7787-mediated cisplatin nephroprotec...
2010-04-01
[Cancer Chemother. Pharmacol. 65(5) , 941-51, (2010)]

Vibrational spectroscopic studies of mesna and dimesna.
2003-06-01
[Spectrochim. Acta. A. Mol. Biomol. Spectrosc. 59(8) , 1791-8, (2003)]

BNP-7787 (BioNumerik/Baxter Oncology/Grelan).

Abstract

Related Compounds